Electroconvulsive Therapy in Clozapine-resistant Schizophrenia
NCT ID: NCT02159001
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2014-06-30
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
NCT00042224
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
NCT03807882
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)
NCT00753051
Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study
NCT01948999
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
NCT06456983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ECT treatment right after recruitment
This group receives electroconvulsive therapy treatment right after they are recruited.
electroconvulsive therapy
10-course, three times a week bilateral frontotemporal ECT
ECT after 4 weeks period.
This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
electroconvulsive therapy
10-course, three times a week bilateral frontotemporal ECT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
electroconvulsive therapy
10-course, three times a week bilateral frontotemporal ECT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment-resistant to clozapine
* age 18 - 64 years
* capacity and willingness to give informed consent
Exclusion Criteria
* progressive neurological illness, recent brain damage or sequela of serious brain damage
* ECT less than 3 months prior to this trial
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Niuvanniemi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Niuvanniemi Hospital
Kuopio, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.